Search results will open in a new window on

Exchange Bulletin

Medicenna Therapeutics Corp. (MDNA) To Trade On Toronto Stock Exchange

July 31, 2017
Issuer: Medicenna Therapeutics Corp. ("Medicenna")
Security: Common Shares (the "Shares")
Symbol: MDNA
Number of securities issued and outstanding: 24,344,048 Shares
Number of securities reserved for issuance: 5,732,309 Shares
Listing category: Industrial, Non-Exempt Issuer
CUSIP: 58490H 10 7
Trading currency: CDN$
Listing and posted for trading date: August 2, 2017 (at the opening)
Other market(s): The Shares have been listed on TSX Venture Exchange ("TSXV") since March 8, 2017 and traded under the symbol "MDNA". The Shares will be delisted from TSXV on August 2, 2017, upon commencement of trading on Toronto Stock Exchange.
Temporary market maker: Integral Wealth Securities Limited
Investor relations: Fahar Merchant
Chief Executive Officer and President
(604) 671-6673
Email :
Elizabeth Williams
Chief Financial Officer
(416) 648-5555
Email :
Incorporation: Business Corporations Act (Alberta)
Fiscal year end: March 31
Nature of business: Medicenna is a clinical stage immunotherapy company developing proprietary super agonist and antagonist versions of cytokines called SuperkinesTM. MDNA55 is the Medicenna's lead Empowered CytokinesTM in clinical development for the treatment of brain cancers.
Transfer agent and registrar: TSX Trust Company at its principal office in Toronto
Dividends: None anticipated in the foreseeable future
Sponsorship: Bloom Burton Securities Inc.
TSX contact: Julie K. Shin,
Director, Listed Issuer Services,
Toronto Stock Exchange